
JonesTrading analyst Boris Peaker has maintained their bullish stance on CGEM stock, giving a Buy rating today. Boris Peaker’s rating is based on the potential of Cullinan’s CLN-978, a CD19xCD3
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CGEM | Cullinan Management | 8.89 | -0.58 | -6.12% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.89 | -6.12% |

JonesTrading analyst Boris Peaker has maintained their bullish stance on CGEM stock, giving a Buy rating today. Boris Peaker’s rating is based on the potential of Cullinan’s CLN-978, a CD19xCD3

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on CGEM stock, giving a Buy rating on November 10. Robert Burns gave his Buy rating based on several factors,

Cullinan Therapeutics Inc (CGEM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Cullinan Therapeutics Inc faces a looming compliance inflection point as it will cease

JonesTrading analyst Boris Peaker has maintained their bullish stance on CGEM stock, giving a Buy rating yesterday. Boris Peaker has given his Buy rating due to a combination of upcoming

“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have

Cullinan Management ( ($CGEM) ) just unveiled an announcement. On November 8, 2026, Cullinan reported interim data from Genrix Bio’s ongoing Phase 1b/2a trial of velinotamig in patients with active,

Cullinan Therapeutics (CGEM) announced clinical data from the ongoing Genrix Bio Phase 1b/2a study of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, SLE. The results will be

In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Cullinan Management, with a price target of $36.00. Boris Peaker’s rating is based on encouraging clinical

William Blair says abstracts for the upcoming American Society of Hematology Annual Meeting were published, including updated data for Cullinan Therapeutics (CGEM)’ CLN-049 in relapsed/refractory acute myeloid leukemia and myelodysplastic

Cullinan Therapeutics (CGEM) shares are sinking after a data abstract for the company’s T cell engager program, CLN-049, was posted ahead of the American Society of Hematology Annual Meeting and
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 18, 2026 | ||||
| buy | Assigned | Nov 18, 2026 | ||||
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Oct 6, 2026 | ||||
| buy | Reiterated | Sep 24, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 17, 2027TBA | $577.15M | $-0.80 | $0.00 | -0.14 | -2.72 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.